Senior Associate Dean for Research and Strategic Initiatives, Director of Center for Obesity Research and Education, College of Public Health, Temple University
Blue Bell, PA
- Tweets 2,389
- Following 943
- Followers 913
- Likes 21,226
Thrilled to represent @TempleCPH and join @foodtank and @FareRx on this new initiative. Launch event @whyy this afternoon! Philadelphia Food as Medicine Coalition wants to improve health through nutrition inquirer.com/health/food-med… via @phillyinquirer
1
44
David Sarwer retweeted
📚 Did you know World Obesity publishes four leading journals? Obesity Reviews, Pediatric Obesity, Clinical Obesity and Obesity Science & Practice share the latest research on obesity science, prevention and care. 🔬 Explore our journals: ow.ly/IyKA50ZUmvw
#ObesityResearch #ObesityReviews #PediatricObesity
4
6
273
David Sarwer retweeted
📖 From Obesity Reviews, the most highly cited obesity journal, to Pediatric Obesity, Clinical Obesity and Obesity Science & Practice, our four peer-reviewed journals cover the full spectrum of obesity research.
🔗worldobesity.org/resources/j…
#ObesityResearch #GlobalHealth #PublicHealth
4
10
402
David Sarwer retweeted
Systematic Review of the Relationship Between the Presence and Quality of Sidewalks and Children’s Physical Health, published in @ChildObesity_jn
Link to pub: journals.sagepub.com/doi/10.…
1
1
136
So proud of my sister-in-law,
Heather Ellis Cucolo,
Serving as as expert commentator on the Clancy case just now on @BBCWorld. Great job sharing your expertise, Heather!!!
1
97
Pleased to have had the opportunity to talk about the potential of the oral GLP-1s to increase access to obesity treatment. @TempleCPH @TempleResearch @TempleHealth @TempleSBS @thephillyvoice @ObesityAction @WorldObesity
New GLP-1 pills could expand access but cost and inconsistent insurance coverage pose hurdles. As @davidbsarwer @TempleCPH notes: “We need to figure out the best ways we can make these medications affordable… in the short & long term.” @thephillyvoice phillyvoice.com/weight-loss-…
2
3
362
More great and important work by @HamletGasoyan and colleagues on real world use of the GLP-1s to treat #obesity. Studies like this are critical to help us guide policy as well as critical adjunctive strategies to promote enduring obesity management.
In a new study of 7938 patients who initiated semaglutide or tirzepatide for obesity or diabetes and discontinued the medication within 3–12 months, we examined what additional obesity treatment patients pursue and weight changes post-discontinuation.
doi.org/10.1111/dom.70660
1
1
286
David Sarwer retweeted
In a new study of 7938 patients who initiated semaglutide or tirzepatide for obesity or diabetes and discontinued the medication within 3–12 months, we examined what additional obesity treatment patients pursue and weight changes post-discontinuation.
doi.org/10.1111/dom.70660
2
7
21
6,853
David Sarwer retweeted
Participation in a Produce Prescription Observational Cohort Intervention Is Associated with Improvements in Child Fruit and Vegetable Intake, published in @ChildObesity_jn
Link to pub: liebertpub.com/doi/10.1177/2…
2
4
98
Thrilled to have had an opportunity to comment on all of the ads for obesity management medications during the Super Bowl. Public awareness about evidence based treatments is critically important. @TempleCPH @TempleResearch yahoo.com/lifestyle/article/…
1
2
65
Great article on my colleague and collaborator @HamletGasoyan on how he used his experience and training @TempleCPH to become a rapidly rising star at @ClevelandClinic doing impactful work on use of #obesity treatments. @WorldObesity @TempleResearch @ObesitySociety
🔍 From data to decisions: Discover how CPH alum Hamlet Gasoyan, DS, PhD, MPH, is turning real-world obesity research into insights that inform health policy and improve treatment access. 👉 buff.ly/mLkg27C
3
4
445
Great to see this video describing the psychological considerations of metabolic and bariatric surgery to treat #obesity reposted today. Thanks @IfsoSecretariat @WorldObesity @ObesitySociety @TempleCPH @TempleUniv @ObesityAction @WileyHealth
@davidbsarwer highlights an important reality: many patients seeking MBS experience psychosocial distress. These factors influence treatment adherence and wellbeing. Most patients experience major improvements after surgery, but proper psychological preparation is essential.
1
3
75
It was my pleasure to write my Psychosocial Insights commentary for this novel and important study. Great work @ChrisDyMD. @prsjournal @TempleResearch @TempleCPH @TempleSurgery @TempleUniv
This @prsjournal study identifies brachial plexus recovery needs such as patients need education, coordination, and connection.
Read more here: bit.ly/BPIChallenges
@ChrisDyMD
2
3
280
Thrilled to have my recent article in @ConversationUS featured along side those of @marionnestle and @astokespop in this great piece by @ConscienHealth on the importance of obesity prevention and treatment. @TempleCPH @TempleResearch @TempleUniv @WorldObesity @ObesitySociety
We agree when @marionnestle, @astokespop, and @davidbsarwer say don't neglect #ObesityPrevention. But we are suspecting that market dynamics are doing more to bend the curve than many health advocates. It's time to catch up with reality.
conscienhealth.org/2025/12/w…
3
3
1,254
David Sarwer retweeted
We publish four scientific journals featuring the most up to date and cutting-edge research in the field of #obesity.
Free content from each journal is available to read each month.
➡️ Find out more here: worldobesity.org/resources/j…
#FridayFindings
1
2
196
David Sarwer retweeted
🚨 Treatment discontinuation is common in patients receiving semaglutide or tirzepatide for obesity. This is the first US study to quantify the specific reasons for discontinuation in clinical practice.
doi.org/10.1002/oby.70058
ALT Reasons for obesity pharmacotherapy discontinuation by discontinuation timing.
2
3
4
547
David Sarwer retweeted
Reasons for Discontinuation of Obesity Pharmacotherapy With Semaglutide or Tirzepatide in Clinical Practice - Gasoyan - Obesity onlinelibrary.wiley.com/doi/…
4
8
603
RT @BariatricNews: Journal Watch: Our regular round-up includes laparoscopic reversal of gastric bypass, surgery vs GLP-1ras, GLP-1s in a p…
1
Appreciate @BariatricNews picking up our recent article on utilization and potential misuse of GLP-1’s in the absence of training and experience in comprehensive obesity treatment. @TempleCPH @TempleResearch @TempleSBS @ConscienHealth @ObesityAction @prsjournal @WorldObesity
Researchers @TempleCPH are warning how some plastic surgeons (PS) are promoting GLP-1s & using them to treat patients & are treating obesity as a cosmetic issue rather than a chronic disease & have made a series of recommendations to PS prescribing GLP-1s shorturl.at/6IqC9
1
3
170
More outstanding and impactful work by @HamletGasoyan @Ali_Aminian_MD and others from @ClevelandClinic on the health benefits of metabolic surgery. @ASMBS @IfsoSecretariat @WorldObesity @ObesitySociety
New study led by @Ali_Aminian_MD @ClevelandClinic Macrovascular and microvascular outcomes of metabolic surgery vs GLP-1
At the end of the study, patients who underwent surgery had:
• 32% lower risk of death
• 35% lower risk of major adverse cardiovascular events (MACE), such as heart attack, heart failure, or stroke
• 47% lower risk of CKD
• 54% lower risk of retinopathy
nature.com/articles/s41591-0…
3
7
582